Drug Prices
The AHA filed a declaration supporting other organizations seeking a temporary restraining order and preliminary injunction to prevent the Centers for Medicare & Medicaid Services from cutting under its Most Favored Nation Model payments for certain Medicare Part B drugs and biologicals to no…
The Centers for Medicare & Medicaid Services (CMS) Nov. 20 released an interim final rule implementing the Most Favored Nation (MFN) Model, a new payment model through the Center for Medicare and Medicaid Innovation (CMMI) that will cut Medicare Part B payments for certain drugs to the lowest…
The Trump administration announced two actions that it claims will lower prescription drug prices.
Intermountain Healthcare has agreed to sell its Intalere group purchasing organization (formerly Amerinet) to Vizient, a GPO that also provides data analytics and performance-improvement insights to health systems.
Specialty drugs more than doubled as a share of retail fills for the overall U.S. population between 2010 and 2017, according to a study using various sources and published in Health Affairs, growing from 1% to 2.3%.
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary Alex Azar expressing concern about recent efforts by Kalderos to transition the 340B Drug Pricing Program from one of up-front discounts to…
AHA urges HHS to stop drug companies’ refusal to provide required 340B discounts
A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation provides an incomplete picture of U.S. spending on health care while downplaying the “immense role” that drug costs play, writes Aaron Wesolowski, AHA’s vice president of policy research, analytics and…
A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation, “What drives health spending in the U.S. compared to other countries,” does not provide a full picture on health care spending in the U.S. while also downplaying the immense role that drug costs play in…
The House Committee on Oversight and Reform this week concluded a two-day hearing examining pricing practices for some of the nation’s costliest drugs. As part of the hearing, Committee Chairwoman Carolyn Maloney, D-N.Y., released additional staff reports describing repeated actions by drug…